Global Erectile Dysfunction Market

Global Erectile Dysfunction Market Size, Share, Growth Analysis, By Product(Viagra, Cialis) - Industry Forecast 2024-2031

Report ID: SQSG35I2033 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 39 | Figures: 73

Global Erectile Dysfunction Market Regional Insights

The erectile dysfunction industry is expected to be dominated by North America. The prevalence of erectile dysfunction, the well-developed healthcare system, and the accessibility of treatment tools are all factors in the supremacy.

Due to regulatory agencies' evaluation of erectile dysfunction medicines, the market for erectile dysfunction treatments is also anticipated to rise significantly in Europe. The market expansion in this region is projected to be fueled by the rising elderly population as well as many product launches by major market competitors.

The highest CAGR is anticipated to be recorded in the Asia Pacific. Growing patient populations with erectile dysfunction are projected to fuel this region's market expansion as the demand for medications like sildenafil and tadalafil rises.

The markets in the Middle East and Africa, as well as Latin America, are still developing. However, rising patient awareness of the condition and the medication in these areas is probably going to contribute to a sizable increase in the market in the coming years.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Erectile Dysfunction Market size was valued at USD 2.3 billion in 2019 and is poised to grow from USD 2.49 billion in 2023 to USD 4.73 billion by 2031, growing at a CAGR of 8.5% in the forecast period (2024-2031).

Key market participants in the erectile dysfunction (ED) drugs market are strengthening their market positions by implementing a variety of strategies, including mergers and acquisitions and research partnerships with other businesses, to introduce novel products and solidify their market positions globally. For instance, due to a production error, Sun Pharmaceutical Industries Ltd. announced the recall of their generic medicine Tadalafil in November 2021. A small gap in the availability of generic ED medications used to treat erectile dysfunction patients may result from this recall. 'Pfizer Inc.', 'Eli Lilly and Company', 'Bayer AG', 'VIVUS, Inc.', 'Dong-A ST Co. Ltd.', 'Meda Pharmaceuticals Inc.', 'S.K. Chemicals Co. Ltd.', 'Teva Pharmaceutical Industries Ltd.', 'Endo International plc', 'Futura Medical plc', 'Apricus Biosciences, Inc.', 'Medtronic plc', 'Coloplast Corp.', 'Boston Scientific Corporation', 'Zephyr Surgical Implants', 'Urologix, LLC', 'American Medical Systems, Inc.', 'Augusta Medical Systems, LLC', 'Pos-T-Vac Medical'

Diabetes, obesity, and cardiovascular disease are on the rise due to the rise in the adoption of an unhealthy lifestyle, which in turn causes issues like ED as people age. Young people's current lifestyles are particularly stressful in many emerging nations, which has led to an increase in fast food and ready-to-eat food consumption as well as drinking and smoking. These variables are compromising general health and fitness, which in turn raises the risk of ED. Additionally, the number of ED patients increases along with the senior population growth, which continues to be a major driver of the worldwide erectile dysfunction medications market during the projection period.

The medication sildenafil is used to treat erectile dysfunction. By boosting blood flow to the penis, it aids males in obtaining an erection. At least two-thirds of the men who took it said their erections got better. The drug sildenafil is used to treat pulmonary arterial hypertension and erectile dysfunction, among other conditions. It is marketed under the trade name Viagra among others. Its efficacy in treating female sexual dysfunction has not been shown. The most popular medication used as initial therapy for erectile dysfunction is sildenafil (Viagra). So, throughout the projection period, the segment is anticipated to grow due to the success of Viagra (sildenafil citrate) in the treatment of erectile dysfunction.

The erectile dysfunction industry is expected to be dominated by North America. The prevalence of erectile dysfunction, the well-developed healthcare system, and the accessibility of treatment tools are all factors in the supremacy.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Erectile Dysfunction Market

Report ID: SQMIG35I2291 | Region: Global | Published Date: February, 2024 | Pages: 165 | Tables: 117 | Figures: 77

Global Veterinary Immunodiagnostics Market
Buy Now GET FREE SAMPLE
Global Erectile Dysfunction Market

Report ID: UCMIG35I2264 | Region: Global | Published Date: February, 2024 | Pages: 165 | Tables: Figures:

Dermatology Drugs Market
Buy Now GET FREE SAMPLE
Global Erectile Dysfunction Market

Report ID: UCMIG35I2169 | Region: Global | Published Date: February, 2024 | Pages: 165 | Tables: Figures:

Monoclonal Antibodies In Veterinary Health Market
Buy Now GET FREE SAMPLE
Global Erectile Dysfunction Market

Report ID: SQMIG35I2060 | Region: Global | Published Date: February, 2024 | Pages: 157 | Tables: 88 | Figures: 76

Global Cannabis Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Erectile Dysfunction Market

Product ID: SQSG35I2033

$5,300
BUY NOW GET FREE SAMPLE